
UCB, a global biopharmaceutical company, has launched Zilbrysq (zilucoplan) in the US for treating generalized myasthenia gravis (gMG) in adults with anti-acetylcholine receptor (AChR) antibodies. Approved by the FDA on October 17, 2023, Zilbrysq is administered daily via a pre-filled syringe. Prescribers must enroll in the Zilbrysq REMS due to meningococcal infection risks. Common side effects include injection site reactions, upper respiratory tract infections, and diarrhoea. UCB's Onward program offers support for those managing myasthenia gravis, emphasizing affordable access to their FDA-approved treatments, Zilbrysq and Rystiggo, for the rare disease community. Eligible patients gain access to personalized resources through the Onward patient support program.
Like
Save
Share